Senate Majority Leader John Thune Moves to Advance Crypto Clarity Act 
Canada, US Hold Constructive Trade Talks as Tariff Negotiations Continue 
Russian Strikes on Ukraine Kill Six, Wound Dozens in Balakliia and Sumy 
China Exports Beat July Forecasts as AI Demand Fuels High-Tech Trade 
Australia Trade Surplus Returns in June as Iron Ore, Coal and LNG Exports Surge 
US Dollar Gains as Iran Tensions, Fed Rate Hike Bets Rise 
US Dollar Falls as Weak July Jobs Report Dents Fed Rate Hike Bets 
ICE to Complete Nationwide Body Camera Rollout by End of August 
India Plans Tax Reforms to Boost Foreign Investment and Manufacturing 
Gold Prices Steady as Hormuz Tensions Fuel Fed Rate Concerns 
Trump Administration to Ban Chinese Robots, Power Inverters Over AI Security Concerns 
Appeals Court Rejects Trump Bid to Reinstate $100,000 H-1B Visa Fee 
Oil Prices Surge as Iran Hormuz Restrictions Renew Supply Fears 
BOJ Rate Hike Expectations Rise Ahead of September Meeting 
Ukraine Agrees to Protect Kazakhstan Oil Exports via Black Sea 
Trump Unveils $3 Billion U.S. Critical Minerals Push 
U.S. President Donald Trump announced sweeping new trade tariffs Thursday evening, including a 100% levy on imported pharmaceutical products, marking one of his most aggressive moves to date in reshaping America’s trade policy. The new tariffs, set to take effect October 1, will also include a 25% duty on heavy truck imports, 50% on kitchen and bathroom fittings, and 30% on upholstered furniture.
According to Trump, the pharmaceutical tariffs will apply to all branded or patented products, though companies actively building manufacturing plants in the United States will be exempt. He specified that firms must have already broken ground or begun construction on U.S. facilities to qualify. Trump framed the move as a matter of national security and a necessary step to reduce dependency on foreign drug imports.
The United States imported over $212 billion worth of pharmaceutical products in 2024, government data shows. Trump has long criticized this reliance, arguing that it threatens U.S. security and weakens domestic industries. Earlier this year, he demanded that 17 major drugmakers lower domestic drug prices while raising them abroad to balance profits. In August, Trump warned he could hike tariffs as high as 250%, signaling the seriousness of his push for reshoring production.
The tariff threats have already spurred huge investment pledges from global pharma companies. Roche committed to investing $50 billion, while Novartis announced $23 billion in U.S. facilities. American firms including Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are also ramping up domestic operations to hedge against the new trade policies.
These tariffs extend beyond pharmaceuticals, targeting industries like heavy trucks, fittings, and furniture—sectors Trump says need protection to revive U.S. manufacturing and safeguard jobs. While the full impact of these measures on trade partners remains unclear, they underscore the administration’s continued reliance on tariffs as a core tool in its economic agenda.
